{
    "organizations": [],
    "uuid": "40a33bedef8077ab12ac539b350d9957063c0571",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-eiger-biopharmaceuticals-reports-f/brief-eiger-biopharmaceuticals-reports-first-quarter-2018-financial-results-idUSASC0A1RQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Eiger Biopharmaceuticals Reports First Quarter 2018 Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Eiger BioPharmaceuticals Inc:\n* EIGER BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.84 * Q1 EARNINGS PER SHARE VIEW $-1.04 â€” THOMSON REUTERS I/B/E/S\n* AS OF MARCH 31, 2018, EIGER HAD CASH, CASH EQUIVALENTS AND SHORT-TERM DEBT SECURITIES OF $33.2 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-11T20:05:00.000+03:00",
    "crawled": "2018-05-12T17:24:19.043+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "eiger",
        "biopharmaceuticals",
        "inc",
        "eiger",
        "biopharmaceuticals",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "march",
        "eiger",
        "cash",
        "cash",
        "equivalent",
        "debt",
        "security",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}